Azithromycin reduces inflammation in infant cystic fibrosis: trial
The treatment could be considered routinely for early management, Australian researchers say
Azithromycin treatment from diagnosis of cystic fibrosis in newborns can significantly reduce airway inflammation and hospitalisations, a landmark Australian and New Zealand study finds.
Although the macrolide failed to reduce the extent of structural lung damage, the Telethon Kids Institute-led team in Perth say it could still be considered for routine early management of paediatric cases.
